Pharmaceutical & medical
necessary assurance be provided to doctors and patients in the accuracy of diagnoses and more personalised therapeutic decisions. The evaluation and reduction of
measurement uncertainty will also be essential to reducing the costs of repeat testing. This also has the potential to enable detection of the signs of disease at an earlier stage in its development. Improving and validating emerging imaging techniques through the routine use of data will therefore enable their translation from a research tool to clinical use. Presently, the metrological traceability of
quantitative diagnostics is underdeveloped, which is limiting the translation of novel technologies to the clinic. Therefore, research focused on developing traceable and reliable procedures for improved imaging resolution, sensitivity, quantification and discriminating power is needed. The increasing complexity, and thus cost, of health metrology demands, emphasises the need for a collaborative R&D approach to developing capability involving healthcare providers, NMIs, academia and industry.
‘‘
MeDical iMaging Ultrasound and magnetic resonance imaging (MRI) are non-invasive, non-ionising imaging techniques with potential application in understanding the role of blood flow dynamics in health and disease. These imaging techniques are used widely for quantification of blood velocity and related quantities. However, the clinical exploitation of existing and new haemodynamic measurements using these modalities is dependent upon the development of measurement standards (flow standards) to deliver reproducible imaging results for research, diagnosis and treatment. Diagnosing and treating cardiovascular
diseases is increasingly reliant upon quantitative blood velocity measurement to improve objectivity in clinical decisions across imaging centres and geographies. Standardising the use of medical imaging through the development of experimental and synthetic flow phantoms and documentary standards and guidelines will bridge the existing gap by moving towards traceable, accurate and reproducible measurement. In turn, this will bring
Delivering advances in flow
measurement capability will transform the prevention, early diagnosis and treatment of chronic diseases and ensure the healthy ageing of individuals.
’’
diagnostic confidence, earlier intervention, personalised therapeutic decisions and enhanced patient outcomes. There is a need to establish a flow
metrology infrastructure to support the optimisation and innovation of ultrasound, MRI and other medical imaging systems. This will result in lower manufacturing costs and improved time to market and, ultimately, lead to better performance and accuracy of imaging systems. Furthermore, standardised flow phantoms should act as enablers of increased uptake of new imaging technologies amongst clinical and research communities.
Future DevelopMents There is a clear need to develop expertise and capability in the flow measurement and characterisation of pharmaceutical powder and fluid flows within a continuous manufacturing environment to realise quality, yield and cost benefits. Also, within the clinical setting, non-invasive cardiovascular flow and haemodynamic assessment is currently underdeveloped. One approach to tackling this is through improvement in the quantification, traceability and reproducibility of medical imaging, vital to accelerating its clinical utility. Delivering advances in flow measurement
capability within these crucial areas will impact positively upon the vision of the healthcare and pharmaceutical sectors to transform the prevention, early diagnosis and treatment of chronic diseases and ensure the healthy aging of individuals.
TÜV SÜD National Engineering Laboratory
www.tuvsud.com/en-gb/nel
16
June 2021 Instrumentation Monthly
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78
